FACL6 Antibody (Center) Blocking Peptide
€363.00
In stock
SKU
AC-BP2537b
Background:
FACL6 is involved in activation of long-chain fatty acids for both synthesis of cellular lipids, and degradation via beta-oxidation. It plays an important role in fatty acid metabolism in brain and the acyl-CoAs produced may be utilized exclusively for the synthesis of the brain lipid. FACL6 is expressed predominantly in erythrocyte precursors, in particular in reticulocytes, fetal blood cells derieved from fetal liver, haemopoietic stem cells from cord blood, bone marrow, and brain. Expression is low at earlier stages of erythroid development but is very high in reticulocytes. This protein is involved in myelodysplastic syndrome (MDS) with basophilia, acute myelogenous leukemia (AML) with eosinophilia, and acute eosinophilic leukemia (AEL). It is characterized by a chromosomal translocation t(5;12)(q31;p13) that involves ETV6 and ACSL6.
Other Names:
Long-chain-fatty-acid--CoA ligase 6, Long-chain acyl-CoA synthetase 6, LACS 6, ACSL6, ACS2, FACL6, KIAA0837, LACS5
Target/Specificity:
The synthetic peptide sequence used to generate the antibody AP2537b was selected from the Center region of human FACL6 . A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.
Gene Name: ACSL6 (HGNC:16496)
Gene ID: 23305
Primary Accession: Q9UKU0
Other Accession: ACSL6_HUMAN
Format: Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.
FACL6 is involved in activation of long-chain fatty acids for both synthesis of cellular lipids, and degradation via beta-oxidation. It plays an important role in fatty acid metabolism in brain and the acyl-CoAs produced may be utilized exclusively for the synthesis of the brain lipid. FACL6 is expressed predominantly in erythrocyte precursors, in particular in reticulocytes, fetal blood cells derieved from fetal liver, haemopoietic stem cells from cord blood, bone marrow, and brain. Expression is low at earlier stages of erythroid development but is very high in reticulocytes. This protein is involved in myelodysplastic syndrome (MDS) with basophilia, acute myelogenous leukemia (AML) with eosinophilia, and acute eosinophilic leukemia (AEL). It is characterized by a chromosomal translocation t(5;12)(q31;p13) that involves ETV6 and ACSL6.
Other Names:
Long-chain-fatty-acid--CoA ligase 6, Long-chain acyl-CoA synthetase 6, LACS 6, ACSL6, ACS2, FACL6, KIAA0837, LACS5
Target/Specificity:
The synthetic peptide sequence used to generate the antibody AP2537b was selected from the Center region of human FACL6 . A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.
Gene Name: ACSL6 (HGNC:16496)
Gene ID: 23305
Primary Accession: Q9UKU0
Other Accession: ACSL6_HUMAN
Format: Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.
| Is Featured? | No |
|---|
Write Your Own Review